Amanote Research
Register
Sign In
A Myeloablative Conditioning Regimen With Fludarabine Demonstrates Good Results in UCBT for 30 Pediatric Patients With Hematologic Malignancies, Especially Acute Lymphoblastic Leukemia
Neoplasma
- Slovakia
doi 10.4149/neo_2014_073
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Date
January 1, 2014
Authors
J. TONG
Z. SUN
H. LIU
L. GENG
K. DING
X. WANG
C. ZHENG
B. TANG
X. ZHU
W. YAO
K. SONG
X. LIU
Publisher
AEPress, s.r.o.
Related search
Radiation-Free Allogeneic Conditioning With Fludarabine, Carmustine, and Thiotepa for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies Necessitating Enhanced Central Nervous System Activity
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Significance of an Intensified Myeloablative Conditioning Regimen for Myeloid Malignancy and Acute Lymphoblastic Leukemia
Journal of Hematopoietic Cell Transplantation
Reduced Intensity vs Myeloablative Conditioning Regimen for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Non-Myeloablative Conditioning With Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia
Haematologica
Hematology
Double-Unit Cord Blood Transplantation After Myeloablative Conditioning for Patients With Hematologic Malignancies: A Multicenter Phase II Study in Japan
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Combining Clofarabine and Fludarabine With Exposure Targeted Busulfan for Pediatric Leukemia: An Effective, Low Toxicity TBI-Free Conditioning Regimen
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Pediatric Acute Lymphoblastic Leukemia
Hematology & Transfusion International Journal
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Survival Benefit of Intravenous Busulfan (120 Mg/M2) and Fludarabine Myeloablative Regimen for Treatment of Myeloid Malignancies
Journal of Stem Cell Research & Therapy
